tbuckley/cabot-search huggingface dataset:
High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008
Authors: Uta Dirksen, Bernadette Brennan, Marie-Cécile Le Deley, Nathalie Cozic, Henk van den Berg, Vivek Bhadri, Bénédicte Brichard, Line Claude, Alan Craft, Susanne Amler, Natalie Gaspar, Hans Gelderblom, Robert Goldsby, Richard Gorlick, Holcombe E. Grier, Jean-Marc Guinbretiere, Peter Hauser, Lars Hjorth, Katherine Janeway, Heribert Juergens, Ian Judson, Mark Krailo, Jarmila Kruseova, Thomas Kuehne, Ruth Ladenstein, Cyril Lervat, Stephen L. Lessnick, Ian Lewis, Claude Linassier, Perrine Marec-Berard, Neyssa Marina, Bruce Morland, Hélène Pacquement, Michael Paulussen, R. Lor Randall, Andreas Ranft, Gwénaël Le Teuff, Keith Wheatley, Jeremy Whelan, Richard Womer, Odile Oberlin, Douglas S. Hawkins
Journal: Journal of Clinical Oncology (2019)

PURPOSE The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy with WLI in Ewing sarcoma (ES) presenting with pulmonary and/or pleural metastases. METHODS From 2000 to 2015, we enrolled patients younger than 50 years of age with newly diagnosed ES and with only pulmonary or pleural metastases. Patients received chemotherapy with six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) and one course of vincristine, dactinomycin, and ifosfamide (VAI) before either BuMel or seven courses of VAI and WLI (VAI plus WLI) by randomized assignment. The analysis was conducted as intention to treat. The estimates of the hazard ratio (HR), 95% CI, and P value were corrected for the three previous interim analyses by the inverse normal method. RESULTS Of 543 potentially eligible patients, 287 were randomly assigned to VAI plus WLI (n = 143) or BuMel (n = 144). Selected patients requiring radiotherapy to an axial primary site were excluded from randomization to avoid excess organ toxicity from interaction between radiotherapy and busulfan. Median follow-up was 8.1 years. We did not observe any significant difference in survival outcomes between treatment groups. Event-free survival was 50.6% versus 56.6% at 3 years and 43.1% versus 52.9% at 8 years, for VAI plus WLI and BuMel patients, respectively, resulting in an HR of 0.79 (95% CI, 0.56 to 1.10; P = .16). For overall survival, the HR was 1.00 (95% CI, 0.70 to 1.44; P = .99). Four patients died as a result of BuMel-related toxicity, and none died after VAI plus WLI. Significantly more patients in the BuMel arm experienced severe acute toxicities than in the VAI plus WLI arm. CONCLUSION In ES with pulmonary or pleural metastases, there is no clear benefit from BuMel compared with conventional VAI plus WLI.
TCT-105 Diagnostic Performance of Fractional Flow Reserve and Instantaneous Wave-Free Ratio in LAD and Non-LAD: Results of Iberian-Dutch-English (IDEAL) LAD Study
Authors: Yuetsu Kikuta, Mauro Echavarria Pinto, Guus de Waard, Sukhjinder Nijjer, Hernan Mejia-Renteria, Yasutsugu Shiono, Gilbert Wijntjens, Rasha Al-Lamee, Martijn Meuwissen, Ricardo Petraco, Jan Piek, Niels van Royen, Javier Escaned, Justin Davies
Journal: Journal of the American College of Cardiology (2019)
TCT-50 Comparison of Saline and Radiographic Contrast for Optical Coherence Tomography-Guided Intracoronary Imaging
Authors: Ankita Gore, Evan Shlofmitz, Allen Jeremias, Craig Porter, Fernando Sosa, Mitsuaki Matsumura, Ajay Jayant Kirtane, Jeffrey W. Moses, Martin Leon, Dimitri Karmpaliotis, Hussein Rahim, Gary Mintz, Gregg Stone, Akiko Maehara, Richard Shlofmitz, Ziad Ali
Journal: Journal of the American College of Cardiology (2019)
Financial conflicts of interest amongst abstracts, speakers, and planning committee members at the American Society of Clinical Oncology Annual Meeting
Authors: K. L. Johnston, R. S. Go
Journal: Journal of Clinical Oncology (2007)

6635 Background: Financial conflicts of interest (COI) in medical research are an issue under scrutiny due to a potential risk for biased information. The objective of this study was to survey the extent of self-reported financial relationships with industry amongst abstracts, speakers, and planning committee members at the American Society of Clinical Oncology (ASCO) Annual Meeting. Methods: We used the 2005 and 2006 ASCO meeting program books to tally the total number of abstracts (all types), speakers for education (faculty) and abstract sessions (discussant), as well as planning committee (education and scientific) members (data available only for 2006). The number and nature of financial disclosures were noted. COI categories include: employment, consultant role, stock ownership, honoraria, research funding, expert testimony, or other remuneration. Results are presented as an average over 2 years whenever appropriate. Results: There were approximately 4,396 abstracts presented, 678 speakers, and 301 planners each year. COI were reported in 27%, 46.8%, and 67.4% amongst abstracts presented, speakers, and planners, respectively. Within reported COI, the most common were consultant or advisory role (24.6%), honoraria (21.7%), research funding (21.7%), employment (15.2%), and stock ownership (12.6%). Amongst abstracts with COI, 27.4%, 27.1%, and 45.5% reported 1, 2, or ≥ 3 COI, respectively. Amongst speakers and planners with COI, 35.9%, 38.1%, and 26% reported 1, 2, or ≥ 3 COI, respectively. Notably, COI disclosure was not provided by 14.8% of the speakers on time for the program book publication. Conclusions: Financial COI are prevalent amongst presentations and more so amongst speakers and planners at the ASCO annual meeting. A large proportion of speakers failed to provide disclosure on time. The overwhelming majority of the disclosures were COI other than research funding. While the actual impact of COI on the clinical and research practices of oncologists and researchers cannot be determined from our study, the potential for such influence is significant. No significant financial relationships to disclose.
TCT-529 Novel Predictors New Persistent Left Bundle Branch Block After Evolut TAVR
Authors: Syed Zaid, Aditya Sengupta, Kimberly Okoli, Melissa Tsoi, Asaad Khan, Hasan Ahmad, Joshua Goldberg, Cenap Undemir, Nish Patel, Muhammad Khan, Eisha Gupta, Jason Kovacic, Steven Lansman, George Dangas, Samin Sharma, Annapoorna Kini, Gilbert Tang
Journal: Journal of the American College of Cardiology (2019)
TCT-6 Incidence and Predictors of Hemodynamic Deterioration of Transcatheter and Surgical Bioprosthetic Aortic Valves: Pooled Analysis From the CoreValve Pivotal Trials
Authors: Daniel O'Hair, Michael Reardon, Steven Yakubov, G. Michael Deeb, Lars Søndergaard, Nicolas Van Mieghem, Jeffrey Popma
Journal: Journal of the American College of Cardiology (2019)
TCT-787 Transradial Versus Transfemoral Access for Cardiac Catheterization: A Nationwide Survey of Training Preferences, Expertise, and Comfort Among Cardiovascular Fellows and Teaching Faculty
Authors: Mubbasher Syed, Khalid Hamid Changal, Ealla Atari, Ehab Eltahawy
Journal: Journal of the American College of Cardiology (2019)
TCT-40 Transcatheter Versus Surgical Pulmonic Valve Replacement in the United States
Authors: Sanjay Venkatesh, Sameer Arora, Ryan Max, Paula Strassle, Rahulkumar Singh, Elman Frantz, Mirnela Byku, Pei-Hsiu Huang, Mahesh Sharma, Michael Yeung
Journal: Journal of the American College of Cardiology (2019)
Peripheral Vasoconstriction During Mental Stress and Adverse Cardiovascular Outcomes in Patients With Coronary Artery Disease
Authors: Jeong Hwan Kim, Zakaria Almuwaqqat, Muhammad Hammadah, Chang Liu, Yi-An Ko, Bruno Lima, Samaah Sullivan, Ayman Alkhoder, Rami Abdulbaki, Laura Ward, J. Douglas Bremner, David S. Sheps, Paolo Raggi, Yan V. Sun, Amit J. Shah, Viola Vaccarino, Arshed A. Quyyumi
Journal: Circulation Research (2019)

Rationale: Excessive vasoconstriction in response to mental stress may be a potential mechanism by which acute psychological stress leads to adverse cardiac events. Objectives: We investigated whether excessive digital vasoconstriction during acute mental stress predicts adverse cardiovascular outcomes among patients with coronary artery disease. Methods and Results: Five hundred forty-nine patients with stable coronary artery disease (age 63±9, 76% male, 29% black) underwent mental stress testing with a standardized public speaking stressor and followed prospectively for cardiovascular end points. Digital pulse wave amplitude was continuously measured using peripheral artery tonometry (PAT, Itamar Inc). Stress/rest PAT ratio (sPAT) of pulse wave amplitude during mental stress/baseline was calculated and dichotomized by the median value into low and high sPAT ratio groups. Upon 3-year follow-up, Fine and Gray’s subdistribution hazard ratios were used to examine the association between sPAT ratio and the composite end point of cardiovascular death, myocardial infarction, revascularization, and hospitalization for heart failure. The median sPAT ratio was 0.68 (interquartile range, 0.48–0.88), indicating 32% vasoconstriction with mental stress. Men were more likely to have low sPAT ratio than women (odds ratio, 1.79; P =0.007) while those on β-blockers were less likely to have low sPAT ratio (odds ratio, 0.52; P =0.003). After adjusting for demographic and cardiovascular risk factors, medications, and rate-pressure product change during mental stress, those with low sPAT ratio were at significantly higher risk of adverse outcomes (subdistribution hazard ratio, 1.77 [95% CI, 1.12–2.80]). Conclusions: Greater peripheral vasoconstriction with mental stress, denoted by a low sPAT ratio, is associated with a higher risk of adverse cardiovascular outcomes in patients with coronary artery disease.
The long road to stone management in the bile duct – what else to wish?
Authors: Jonah Cohen, Douglas Pleskow
Journal: Endoscopy (2019)

Despite significant advances in endoscopic retrograde cholangiopancreatography (ERCP) within the past several decades, difficult bile duct stones have remained a persistent clinical challenge for therapeutic endoscopists. In this issue of Endoscopy, Maydeo et al. describe the use of peroral cholangioscopy (POCS)-guided lithotripsy in a single session of ERCP for the clearance of difficult bile duct stones [1]. Their prospective multinational registry evaluated 156 patients and demonstrated a high clinical success rate (80 %) for stone clearance in a single POCS procedure with a low serious adverse event rate (1.9 %).
TCT-41 A Prospective Multicenter Randomized All-Comers Trial to Assess the Safety and Effectiveness of the Ultra-Thin-Strut Sirolimus-Eluting Coronary Stent Supraflex: 2-Year Results of the TALENT Trial
Authors: Patrick Serruys, Azfar Zaman, Robert de Winter, Norihiro Kogame, Rodrigo Modolo, Pim Tonino, Sjoerd H. Hofma, Pieter Smits, Janusz Prokopczuk, Raul Moreno, Anirban Choudhury, Ivo Petrov, Angel Cequier, Neville Kukreja, Imre Ungi, Antonio Serra, Robert Gil, Simon Walsh, Anthony Mathur, Bela Merkely, Antonio Colombo, Alexander Ijsselmuiden, Osama Soliman, Yoshinobu Onuma
Journal: Journal of the American College of Cardiology (2019)
TCT-631 Comparison Between the Use of Overlapping Stents and Very Long Stents in the Diabetic Population With Diffuse Coronary Artery Disease. A Real-Life Study
Authors: Martin Negreira-Caamaño, José Abellán-Huerta, Alfonso Jurado-Román, Ignacio Sanchez-Perez, Pedro Pérez-Díaz, María López-Lluva, Ramón Maseda Uriza, Jesús Piqueras Flores, Jorge Martinez del Río, Fernando Lozano
Journal: Journal of the American College of Cardiology (2019)
Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial
Authors: Daniela Jakubowicz, Zohar Landau, Shani Tsameret, Julio Wainstein, Itamar Raz, Bo Ahren, Nava Chapnik, Maayan Barnea, Tali Ganz, Miriam Menaged, Naomi Mor, Yosefa Bar-Dayan, Oren Froy
Journal: Diabetes Care (2019)

OBJECTIVE In type 2 diabetes, insulin resistance and progressive β-cell failure require treatment with high insulin doses, leading to weight gain. Our aim was to study whether a three-meal diet (3Mdiet) with a carbohydrate-rich breakfast may upregulate clock gene expression and, as a result, allow dose reduction of insulin, leading to weight loss and better glycemic control compared with an isocaloric six-meal diet (6Mdiet). RESEARCH DESIGN AND METHODS Twenty-eight volunteers with diabetes (BMI 32.4 ± 5.2 kg/m2 and HbA1c 8.1 ± 1.1% [64.5 ± 11.9 mmol/mol]) were randomly assigned to 3Mdiet or 6Mdiet. Body weight, glycemic control, continuous glucose monitoring (CGM), appetite, and clock gene expression were assessed at baseline, after 2 weeks, and after 12 weeks. RESULTS 3Mdiet, but not 6Mdiet, led to a significant weight loss (−5.4 ± 0.9 kg) (P &amp;lt; 0.01) and decreased HbA1c (−12 mmol/mol [−1.2%]) (P &amp;lt; 0.0001) after 12 weeks. Fasting glucose and daily and nocturnal glucose levels were significantly lower on the 3Mdiet. CGM showed a significant decrease in the time spent in hyperglycemia only on the 3Mdiet. Total daily insulin dose was significantly reduced by 26 ± 7 units only on the 3Mdiet. There was a significant decrease in the hunger and cravings only in the 3Mdiet group. Clock genes exhibited oscillation, increased expression, and higher amplitude on the 3Mdiet compared with the 6Mdiet. CONCLUSIONS A 3Mdiet, in contrast to an isocaloric 6Mdiet, leads to weight loss and significant reduction in HbA1c, appetite, and overall glycemia, with a decrease in daily insulin. Upregulation of clock genes seen in this diet intervention could contribute to the improved glucose metabolism.
National clinical-biological prospective cohort of incident cases of aggressive fibromatosis, AF (ALTITUDES)
Authors: T. Ryckewaert, N. Penel, M.C. Le Deley, J. Thery, E. Decoupigny, M. Vanseymortier, A. Dufresne, N. Corradini, J.-Y. Blay, D. Orbach, S. Salas
Journal: Annals of Oncology (2019)
Parents of girl with severe brain damage can take her to Italy for treatment, High Court rules
Authors: Clare Dyer
Journal: BMJ (2019)

The parents of a 5 year old girl with irreversible catastrophic brain damage may be taken to Italy for treatment, a High Court judge has ruled.1

Doctors caring for Tafida Raqeeb at the Royal London Hospital asked the court to declare that it would be in her best interests to have life support withdrawn, allowing her to die. But her parents, Shelina Begum and Mohammed Raqeeb, who are devout Muslims, wanted to take her to a hospital in Italy, where only brain stem death justifies withholding treatment, and have arranged funding for her treatment there.

In a case he described as “very finely balanced” Mr Justice MacDonald said, “I am on balance not satisfied that I can conclude on the evidence before the court that life sustaining treatment is no longer …
Selective Depletion of Alloreacting CD25+ Cells from Stem Cell Allografts Can Reduce Acute Graft-Versus-Host Disease Following Matched Related Donor Transplantation.
Authors: Scott R. Solomon, Thao Tran, Charles S. Carter, Nancy Hensel, Laura Wisch, Stephan Mielke, Elizabeth Read, Victor Ghetie, John Schindler, Ellen Vitetta, John Barrett
Journal: Blood (2004)
An Artificial Intelligence Approach for Predicting Allogeneic Hematopoietic Stem Cell Transplantation Outcome By Detecting Pre-Transplant Minimal Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry Data
Authors: Chi-Cheng Li, Bor-Sheng Ko, Yu-Fen Wang, Jeng-Lin Li, Pei-Fang Weng, Hsin-An Hou, Xiu-Wen Liao, Chien-Ting Lin, Jia-Hou Liu, Hsun-I Sun, Hwei-Fang Tien, Chi-Chun Lee, Jih-Luh Tang
Journal: Blood (2017)
Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma
Authors: F. Lefort, C. Dalban, M. Gross-Goupil, B. Laguerre, P. Barthelemy, V. Sarradin, B. Chanez, S. Negrier, L. Geoffrois, P. Gillon, M. De Vries, S. Ladoire, C. Bolognini, M. Laramas, F. Priou, S. Oudard, S. Chabot, F. Tantot, B. Escudier, L. Albiges
Journal: Annals of Oncology (2019)
Increased assessment of HER2 in metastatic gastroesophageal cancer patients: A nationwide population-based cohort study
Authors: W.P.M. Dijksterhuis, R.H.A. Verhoeven, S.L. Meijer, M. Slingerland, N. Haj Mohammad, J. de Vos-Geelen, L.V. Beerepoot, T. Van Voorthuizen, G.-J. Creemers, M. van Oijen, H.W.M. van Laarhoven
Journal: Annals of Oncology (2019)
Abstract 2557: The Appraisal-Trial: Evaluating RESTEN-MPTM in Patients with Bare Metal Stent de novo Native Coronary Artery Lesions
Authors: Sebastian Philipp, Dirk Böse, Igor Kordish, Johannes Brachmann, Klinikum Coburg, Stefan Hardt, Stefan Sack, Raimund Erbel
Journal: Circulation (2008)

Background: Although the use of drug-eluting stents has been shown to limit neointimal hyperplasia, currently available DES may adversely affect re-endothelialization, possibly precipitating late cardiac events. The aim of this study was to evaluate the efficacy and safety of a microbubble delivery of c-myc antisense peptide in preventing restenosis after coronary stenting in de novo stenosis with intravascular ultrasound. Methods: A BMS was implanted in de novo coronary artery lesions (RD ≥ 2.5- ≤4.0mm; TL ≥ 15- ≤ 30mm in length). Serial intravascular ultrasound analysis were performed in 25 lesions. A dose of 16mg RESTEN-MPTM (AVI BioPharma/Global Therapeutics LLC) was intravenously administered after stenting and again 24 hours later. Results: A total of 50 patients were enrolled, 34 in Essen, 13 in Coburg and 3 in Heidelberg. Before stenting, the MLD and length of stenosis was determined by QCA. 18 Patients had a LAD lesion, 21 LCX, 12 RCA. 84% (43/51) of the lesions were either Type B2 or C lesions. At six month follow-up, angiography with a QCA was performed. Generally the neointimal proliferation was minor and open vessel lumen could be demonstrated during follow-up. Of the 30 patients currently studied at six-months in the IVUS sub-study, six patients required TLR. Late lumen loss by QCA was 0.47±0.09mm. Volume stenosis by IVUS was 26 ± 4 %. Generally the neointima proliferation was minor and open vessel lumen could be demonstrated during follow-up. Summary: Microbubble delivery of c-myc antisense seems to be effective in reducing neointimal tissue proliferation without the problem of late stent thrombosis, because the proliferation seems to be attenuated but not fully blocked.
Detection of Activated STAT5 in the Cytoplasm of Neoplastic Cells in Patients with AML, CML, and Systemic Mastocytosis.
Authors: Karoline Sonneck, Richard Fritz, Leonhard Muellauer, Karoline V. Gleixner, Matthias Mayerhofer, Stefan Florian, Marc Kerenyi, Wolfgang R. Sperr, Christian Sillaber, Richard Moriggl, Peter Valent
Journal: Blood (2006)
Involvement of microRNA in the regulation of progesterone receptor in breast cancer.
Authors: Ayelet Shai, Avital Gilam, Mariana Steiner, Noam Shomron
Journal: Journal of Clinical Oncology (2013)

578 Background: The progesterone receptor (PgR) is a prognostic factor in ER positive breast cancers treated by adjuvant hormonal treatment. While PgR protein is usually assessed by immunohistochemistry (IHC), RT-PCR measurement of mRNA levels is provided by Oncotype Dx and other tests. Between 20-40% of tumors are discrepant in IHC and RT-PCR PgR expression, reflecting either technical problems or biological mechanisms. MicroRNAs regulate gene expression either at the mRNA or the protein translation level. Our hypothesis is that the latter potentially explains discrepancies between IHC and RT-PCR results. Methods: ER positive tumors were divided to three groups by PgR expression according to IHC and RT-PCR: (i) positive by IHC; (ii) negative by IHC and high mRNA levels by RT-PCR; (iii) negative by IHC and low mRNA levels by RT-PCR. RNA was extracted from tumors and adjacent normal tissue and the expression of PgR and microRNAs was assessed by RT-PCR. In addition, microRNAs were transfected into MCF-7 cells. The levels of PgR mRNA and protein were analyzed. Results: The PgR gene contains potential conserved binding sites for MicroRNAs 23a, 181a, 135a and 26b. Of these, miR- 23a and miR-181a showed inverse expression relative to the PgR expression in normal and tumor tissue, as expected. MicroRNA levels were determined in tumors of all three groups. The highest expression of microRNAs 23a, 181a and 26b was seen in IHC negative tumors with low levels of mRNA. Intermediate expression was seen in IHC negative tumors with high mRNA levels, and the lowest expression was detected in IHC positive tumors. Preliminary results suggest that over expression of microRNAs 23a, 181a and 26b in MCF7 cells decreased PgR levels. Conclusions: Our results suggest that microRNAs 23a , 181a and 26b regulate the level of the progesterone receptor in breast cancer and that tumors with relatively high mRNA levels may be deficient in PgR protein due to downregulation by microRNAs. [Table: see text]
Mitochondrial DNA determines androgen sensitivity in prostate cancer cell lines
Authors: Masahiro Higuchi, Takahiko Kudo, Teresa T. Evans, Yoshitaka Wada, Toshiro Shirakawa, Akinobu Gotoh
Journal: Cancer Research (2005)

1024  Prostate cancer progresses from an androgen-dependent stage to androgen-independent after androgen ablation therapy. Mitochondrial DNA plays a role in cell death and metastatic competence. Further, heteroplasmic large deletion mitochondrial DNA is very common in prostate cancer. To investigate the role of mitochondrial DNA in androgen dependence of prostate cancers, we tested the changes of normal and deleted mitochondrial DNA in accordance with the progression of prostate cancer. We demonstrate that androgen-independent cell line C4-2, established by inoculation of androgen-dependent LNCaP into castrated mice, as compared with LNCaP, have 8 times reduced expression of normal mitochondrial DNA associated with an accumulation of large deletion. C4-2 has a marked decrease in respiratory function possibly due to the change of mitochondrial DNA. Strikingly, depletion of mitochondrial DNA from androgen-dependent LNCaP resulted in a loss of androgen dependence. Reconstitution of normal mitochondrial DNA to mitochondrial DNA-depleted clone restored androgen dependence. These results indicate that mitochondrial DNA determines androgen dependence of prostate cancer cell lines. Further, mitochondrial DNA-deficient cells formed tumors in castrated athymic mice, whereas LNCaP did not. The accumulation of large deletion and depletion of mitochondrial DNA may thus play a role in the development of androgen independence and progression of prostate cancers.
Intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): A randomized, multicenter, prospective, phase III trial
Authors: R. Zhang, X.-J. Wu, D. Wan, J. Lin, P. Ding, J. Lei, Z. Lu, L. Li, G. Chen, L. Kong, F. Wang, D. Zhang, W. Fan, W. Jiang, W. Zhou, C. Li, Y. Li, X. Li, Z. Pan
Journal: Annals of Oncology (2019)
SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz)
Authors: B.P. Valderrama, S. Perez Ramirez, A. Rodriguez-Vida, A. González del Alba, M.J. Mendez Vidal, S. Vazquez Estevez, E. Martinez Ortega, J.A. Virizuela, O. Fernández Calvo, A. Hernández Jorge, F.J. Vazquez Mazon, M.B. Gonzalez Gragera, M. Campayo, O. Etxaniz Ulazia, E. Almagro Casado, M. Sereno Moyano, M.T. Abad Villar, C. Suarez Rodriguez, E. Gallardo Diaz, J.A. Arranz Arija
Journal: Annals of Oncology (2019)